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Abstract
Background: Both chloroquine (CQ ) and sulfadoxine-pyrimethamine (SP) are failing drugs in 
much of sub-Saharan Africa. Previous findings suggest an association between resistance to CQ  and 
to SP in vivo, in vitro, and on the molecular level.
M ethods: In 126 Ghanaian children with uncomplicated malaria, associations between mutations 
conferring resistance in the Plasmodium falciparum dihydrofolate reductase (dhfr; SP) and chloroquine 
resistance transporter (crt; CQ ) genes, concentrations of residual antimalarial drugs, and gametocyte 
carriage were examined.
Results: Mutant dhfr alleles and the CQ-resistance allele crt T76 were strongly associated with 
each other. Isolates exhibiting the dhfr triple mutation seven times more likely also contained crt 
T76 parasites as compared to isolates without the dhfr triple variant (P = 0.0001). Moreover, both, 
isolates with the dhfr triple mutation (adjusted OR, 3.2 (95%CI, 1.0-10.4)) and with crt T76 
(adjusted OR, 14.5 (1.4-150.8)) were associated with an increased likelihood of pre-treatment 
gametocytaemia. However, crt T76 did not correlate with gametocytaemia following SP treatment 
and no selection of crt T76 in SP treatment failure isolates was observed.
Conclusion: These results confirm an association between CQ  and SP resistance markers in 
isolates from northern Ghana. This could indicate accelerated development of resistance to SP if 
C Q  resistance is already present, or vice versa. Considering the enhanced transmission potential 
as reflected by the increased proportion of isolates containing gametocytes when resistant 
parasites are present, co-resistance can be expected to spread in this area. However, the 
underlying mechanism leading to this constellation remains obscure.
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Background
Chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) 
are the most frequently used antimalarial drugs in sub- 
Saharan Africa. With the spread and intensification of 
drug resistance of Plasmodium falciparum more effective 
combinatory drug regimes are now introduced in many 
African countries [1]. However, CQ and SP are cheap and 
widely available and will most likely be in use for some 
more years, particularly in home treatment [2-4].
In several East African countries where SP was introduced 
in response to intense CQ-resistance, the drug has gradu­
ally lost efficacy although the pace of this development is 
subject to controversy [5,6]. Previously, the core muta­
tions linked with resistance to CQ and SP were found to 
be associated with each other in isolates from southern 
Ghana [7]. Although CQ and SP are structurally unrelated 
and the mutations conferring resistance are located on 
separate chromosomes [8-10], this finding suggests that 
parasites resistant to CQ may acquire resistance to SP 
more easily than sensitive ones, or vice versa. Studies in 
murine models [11] and in vitro [12,13] support this 
hypothesis. If this was true, the spread of CQ resistance 
could pave the way for an accelerated development of SP 
resistance, and thus, bear substantial importance to the 
health systems of affected regions. In addition, transmis­
sion potential may be increased in both SP and CQ resist­
ant parasites [14,15].
Recently, mutations in the P. falciparum dihydrofolate 
reductase (dhfr) gene in northern Ghana were observed not 
only to be predictive for SP treatment failure but also to be 
associated with increased pre-treatment gametocyte car­
riage [16]. Here, associations between dhfr alleles, the core 
mutation in the P. falciparum chloroquine resistance trans­
porter gene (crt T76), residual antimalarials, and gameto- 
cyte carriage in children with uncomplicated malaria were 
re-examined.
Methods
P. falciparum  isolates were collected from children with 
uncomplicated malaria participating in a treatment trial 
in Tamale, Northern Region, Ghana, at the end of the 
rainy season 2002. The results of this trial and on the dhfr 
and dihydropteroate synthetase gene (dhps) patterns are 
described elsewhere [16,17]. In the present report, data 
from all 126 children with complete follow-up after SP 
treatment for whom dhfr and dhps were genotyped are 
analysed. The study protocol was approved by the Ethics 
Committee, Ministry of Health, Northern Region, and by 
the Health Research Unit, Ministry of Health, Accra, and 
parents' informed consent was obtained.
Patients were children aged 6-59  months with uncompli­
cated P. falciparum  monoinfection (> 2,000 < 200,000/p.L)
[18,19]. None had severe malnutrition, a febrile disease 
other than malaria, "danger signs" [18], or severe malaria 
[20]. Treatment consisted of a single dose of SP (25/1.25 
mg/kg, Fansidar, Roche, Switzerland), and success was 
monitored according to current guidelines [17,19].
Venous blood was collected into EDTA. Asexual parasites 
and gametocytes were counted per > 200 and 500 white 
blood cells, respectively, on Giemsa-stained thick blood 
films, and densities were calculated based on a putative 
mean WBC count of 8,000/p.L. Gametocyte counts one 
week following treatment were available for 104 children. 
Pre-treatment levels of CQ and pyrimethamine in blood 
were measured by ELISA assays [21] with limits of detec­
tion of 10 ng/mL and 25 ng/mL, respectively.
P. falciparum dhfr, dhps, and crt alleles were assessed by 
restriction fragment length polymorphisms (RFLP) of 
amplicons generated by nested PCR assays applying hot 
start procedures (HotStart Taq, Qiagen, Germany). Prim­
ers and conditions are described elsewhere [22,23] as are 
restriction enzymes and RFLP conditions to characterize 
the codons dhfr, 16, 51, 59, 108, 164; dhps, 436, 437, 540, 
581, 613; and crt, 76. Laboratory strains were used as con­
trols for PCR and RFLP assays. Electrophoresis was per- 
fomed on 3% GTG agarose (FMC Bioproducts, USA) gels.
Frequencies were compared by %2-test or Fisher's exact 
test, and continuous variables by Student's t-test, Mann­
Whitney U-test, or Kruskal-Wallis test as applicable. Logis­
tic regression models were used to adjust for potential 
confounders of the presence of resistance mutations and 
to identify risk factors for gametocytaemia.
Results
The median age of the 68 girls and 58 boys was 28.5 
months (range, 6 -59). Median axillary temperature and 
geometric mean parasite density were 38.8 °C (range, 
37 .5-41 .0) and 36,358/|iL (range, 2 ,0 6 8 -175,333/|iL), 
respectively. Gametocytes were found in 19% (24/126) of 
the children at a geometric mean density of 50/|iL (1 6 - 
1,120/p.L). CQ in blood was observed in 66% (83/126; 
median, 32 ng/mL, range, 10-718) but pyrimethamine in 
only two children (78 & 326 ng/mL).
The dhfr alleles Thr-108, Val-16 and Leu-164 were not 
detected. Classifying mixed alleles as mutant, dhfr Ile-51 
occurred in 56% (70/126), Arg-59 in 65% (82/126), and 
Asn-108 in 72% (91/126). Triple dhfr mutations (Ile-51/ 
Arg-59/Asn-108) were seen in 47% (59/126), and quad­
ruple (triple dhfr + dhps Gly-437) and quintuple (triple 
dhfr + dhps Gly-437/Glu-540) variants in 44% (55/126), 
and 0.8% (1/126), respectively. Crt T76 occurred in 80% 
(101/126) of the isolates.
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Table 1: Associations between dhfr and c rt  mutations in 126 Ghanaian children w ith  uncom plicated m alaria
dhfr mutation Prevalence of crt T76 mutation (%) Odds ratio (9S%CI) of crt T76 being present
Unadjusted P Adjusted for C Q  in blood* P
Si
absent
present
S9
67.9 (38/S6) 
90.0 (63/70)
i
4.3 (I.S- I2 .S) 0.002
i
S.0 ( i .8— i 3.8) 0.002
absent
present
i08
63.6 (28/44) 
89.0 (73/82)
i
4.6 ( i .7— i 3.0) 0.0007
i
4.4 ( i .7— i i.4) 0.002
absent
present
triple
absent
present
65.7 (23/3S)
85.7 (78/9i)
68.7 (46/67) 
93.2 (SS/S9)
i
3.I ( i .2—8.6) 
i
6.3 ( i .9—26.6)
0.0i
0.0006
i
3.2 (i.2—8.2) 
i
7.0 (2.2—22.S)
0.02
0.00i
dhfr, dihydrofolate reductase gene, crt, chloroquine resistance transporter gene; 95%CI, 95% confidence interval; CQ , chloroquine; *, Potential 
confounders were tested for in logistic regression models including age, sex, parasite density, dhps alleles, and axillary temperature. Adjusted odds 
ratios include the presence of chloroquine in blood as the only factor found to be associated (univariate odds ratio, 3.2; 95%CI, I.2-8.6; P = 0.01).
The concomitant occurrence of dhfr, dhps, and crt alleles in 
identical isolates was analyzed. All dhfr mutations were 
linked with each other. Dhfr Ile-51 was associated with 
Asn-108 (OR, 29.8; 95%CI, 8 .0-161, P < 0.0001) and 
Arg-59 (OR, 7.7; 95%CI, 3 .3-19,5 , P < 0.0001). All iso­
lates exhibiting dhfr Arg-59 additionally had Asn-108 (P < 
0.0001). Notably, in isolates with dhfr variant parasites, 
the CQ-resistance allele crt T76 occurred significantly 
more frequent than in the respective wildtype isolates 
(Tab. 1). Separating isolates into such with e.g. dhfr codon 
108 pure wildtype, wildtype & mutant, and pure mutant, 
the prevalence of crt T76 was 67.5% (23/35), 82.4% (14/ 
17), and 86.5% (64/74), respectively (%2trend = 6.1; P = 
0.01). Basically the same trend was seen for dhfr codons 
51 (P = 0.002) and 59 (P = 0.002, data not shown). Vice 
versa, in isolates with crt wildtype, with both crt wildtype
& T76, and crt T76 alone, the dhfr triple mutation was 
detected in 16% (4/25), 53% (9/17), and 55% (46/84), 
respectively.
The prevalence of crt T76 increased with increasing 
number of any dhfr mutations: it was 63% (20/32) in iso­
lates with pure dhfr wildtype, 74% (26/35) in isolates with 
single or double mutations, and 93% (55/59) in isolates 
exhibiting the dhfr triple mutation (x2trend = 13.1; P = 
0.0003). Adjusting for CQ in blood, isolates with dhfr tri­
ple mutations revealed a seven-fold increased odds of 
concomitantly exhibiting crt T76 (Tab. 1). Dhps alleles 
neither correlated with dhfr alleles nor with crt T76 (data 
not shown).
Dhfr, dhps, and crt alleles were examined with respect to 
pre-treatment gametocytaemia. As reported elsewhere
[16], children were significantly more likely to harbour 
gametocytes in the presence of dhfr 51, 59, or triple muta­
tions. This was also true for isolates exhibiting crt T76 
(Tab. 2 ). Gametocytes were not observed in any (0/21) 
isolate with wildtype alleles for both dhfr and crt, but in 
16% (8/50) of isolates exhibiting either dhfr or crt muta­
tions, and in 29% (16/55) of isolates revealing both, dhfr 
triple and crt T76 (%2trend = 8.7, P = 0.003). Adjusting for 
additional factors influencing gametocytaemia, i.e. high 
parasite density arbitrarily set as >50,000/|iL, the presence 
of CQ in blood, and axillary temperature, both the dhfr 
triple mutation and crt T76 were associated with an 
increased likelihood of gametocytaemia (Tab. 2). Dhfr 
alleles or crt T76 were not associated with gametocyte den­
sity (data not shown).
One week after treatment, gametocytes were observed in 
63% (66/104) of the children. Gametocytaemia following 
SP treatment was associated with pre-treatment dhfr muta­
tions, e.g. dhfr Asn-108, OR 3.1; 95%CI, 1.3-7.6. In chil­
dren harbouring crt T76 parasites, gametocytes were only 
slightly more frequent (66%  (54/82)) than in patients 
with crt wildtype parasites (55% (12/22), P = 0.3).
Finally, selection of crt T76 in SP treatment failures was 
examined. No selection was observed: In matched pairs of 
isolates obtained from 35 children suffering SP treatment 
failure, crt T76 was present in 86% (30/35) of pre-treat­
ment isolates and in 80% (28/35) of isolates obtained at 
treatment failure.
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Table 2: Associations w ith  p re -tre a tm e n t gam etocytem ia  in 126 Ghanaian ch ild ren  w ith  uncom plica ted m alaria
Factor Prevalence of gametocytemia (%) Odds ratio (95%CI) of gametocytemia 
Unadjusted P Multivariate P
CQ in blood 
None 
Present
27.9 (12/43) 
14.5 (l2/83)
l
0.4 (0.2-1.2) 0.07
l
0.3 (0.1-1.0) 0.04
Ax. temperature n.a. 0.3 (0.I-0.6) 0.0008 0.2 (0.I-0.5) 0.0009
Parasite density 
< 50,000/|iL 
> 50,000/|iL
26.3 (20/76) 
8.0 (4/50)
l
0.2 (0.I-0.8) 0.01
l
0.2 (0.I-0.8) 0.02
d h fr triple mutation 
Absent 
Present
10.4 (7/67) 
28.8 (l 7/59)
l
3.5 (1.2-10.2) 0.009
1
3.2 (1.0-10.4) 0.049
crt 76 mutation 
Absent 
Present
4.0 (1/25) 
22.8 (23/101)
l
7.1 (1.0-304) 0.04
1
14.5 (1.4-150.8) 0.02
Ax., axillary; n.a., not applicable
Discussion
In this study on P. falciparum  isolates from northern 
Ghana, two major findings are presented. First, SP and CQ 
resistance markers are strongly associated with each other, 
independent of residual antimalarials. Second, both are 
associated with an increased prevalence of gametocytes.
This study has several limitations and particularly the 
finding of an association between unrelated mutations 
needs caution in interpretation. Because polyclonal infec­
tions predominate in the area [24], the detection of a 
mutant allele in an isolate does not necessarily mean that 
all clones carry the mutation. Thus, it cannot be stated 
whether the linkage between the resistance markers is a 
true one, i.e. on the chromosomal level, or reflects co­
occurrence in individual isolates. The limited number of 
crt wildtypes also hampered proper testing of a linkage 
disequilibrium. Although dhfr mutations were signifi­
cantly more common in the presence of crt T76 this obser­
vation needs to be construed with caution since 80% of 
the isolates in this study harboured the latter variant. Also, 
it is impossible to comment whether the presence of crt 
T76 favours the presence of dhfr mutations or vice versa 
because this requires longitudinal observations. Likewise, 
the lack of temporal information impairs a clear state­
ment on whether resistance mutations bring about 
increased gametocytogenesis. Due to methodology the 
resistance genotype of asexual parasites cannot be sepa­
rated from that of gametocytes.
Despite these difficulties in drawing firm conclusions, sev­
eral previous findings support the hypothesis of a linkage 
disequilibrium between mutations associated with SP
resistance and CQ resistance. Early reports from the 1950s 
and 1960s indicated that in areas or patients with estab­
lished pyrimethamine-resistance in Nigeria, Burkina Faso, 
and Venezuela, CQ exhibited a reduced activity (reviewed 
in [25]). In a murine malaria model, CQ resistance could 
be induced in pyrimethamine-resistant parasites but not 
in sensitive ones [11]. In isolates from Cameroon, the in 
vitro activity of pyrimethamine was ten times lower in CQ 
resistant than in sensitive P. falciparum  [13]. Similar but 
less pronounced differences have also been observed in 
other studies [26,27]. In southern Ghana, we previously 
observed that the dhfr core m utation Asn-108 was three 
times more likely found in isolates exhibiting crt T76 than 
in isolates comprising crt wildtype parasites [7]. The rea­
son for this apparent association between resistance to 
CQ and pyrimethamine or SP is obscure since both drugs 
have distinct modes of action and resistance to these is 
determined by mutations on different chromosomes [8­
10]. One alluringly simple explanation could be that par­
asites in the study area have merely become resistant to 
both drugs, possibly as a result of drug pressure. In this 
regard, previous, simultaneous or sequential treatment 
with CQ and SP could have selected for resistant parasites 
which subsequently persisted for a longer period than the 
drugs can be detected in blood. However, pyrimethamine 
was seen in only two children which indicates that it is 
rarely used in this community and which argues against 
drug-induced selection for SP resistance. In addition, the 
results are corrected for the presence of CQ in blood 
which can be detected for approximately one m onth after 
intake [28]. This does not exclude the possibility of 
selected and persisting parasites but renders it rather 
unlikely. Alternatively, the association between crt T76
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and dhfr mutations could reflect a rapid mutator pheno­
type with the ability of accelerated resistance to multiple 
drugs. This hypothesis originates from in  vitro studies 
observing that parasites resistant to common antimalar- 
ials acquire resistance to structurally unrelated drugs more 
rapidly than susceptible strains. The genetic basis of this 
phenom enon is unknown bu t suggested to involve an 
increased frequency of mutations per se and consequently 
a higher probability of modified proteins which could 
also include drug targets [12]. In fact, selection for high­
grade pyrimethamine resistance in  vitro has been shown to 
enhance the degree of overall genomic polymorphism
[29]. In this regard, it is noteworthy that crt T76 was more 
frequently observed with increasing num ber of dhfr m uta­
tions, i.e. with increasing degree of SP resistance.
In the present study, the association between the resist­
ance markers meets with an increased presence of gameto- 
cytes in isolates comprising m utant dhfr or crt alleles. 
Gametocytaemia seemed to reflect a rather long duration 
of infection as can be deduced from its low prevalence in 
the presence of factors suggestive for acute disease, i.e. 
high body temperature and parasite density, and previous 
CQ treatment (Tab. 2). Again, an increased frequency of 
resistance mutations in gametocytaemic children could 
result from previous drug-related selection as outlined 
above. However, increased gametocytaemia preceding 
treatment has also been observed in infections subse­
quently found to be CQ resistant [30-32]. Hallett et al. 
[15] reported that in patients with crt T7 6 parasites, game- 
tocyte density was highly increased one week following 
CQ treatment. In addition, gametocytes from patients car­
rying crt T76 parasites produced 38 times higher oocyst 
burdens in the mosquito as compared to crt wildtype par­
asites. In Tamale, both residual CQ levels and parasites 
with the crt T76 m utation are abundant [33], and a clear 
association of crt T76 and pre-treatment gametocyte prev­
alence is seen. Only one crt wildtype isolate contained 
gametocytes impairing a sound analysis of the effect of crt 
T76 on gametocyte density. However, increased gameto- 
cyte production by crt T76 parasites [15] in the presence of 
residual CQ could partially explain the present finding. 
The synthesis of both, crt and dhfr mutations being asso­
ciated and increased gametocytaemia in their presence, 
gives rise to a grim scenario: Given that CQ resistant par­
asites have an improved transmission potential [15] the 
association with SP resistance would contribute to an 
accelerating spread of resistance to both drugs, particu­
larly in areas where CQ resistance is frequent. In the 
present study, neither selection of crt T76 in SP treatment 
failure was observed nor a significantly elevated propor­
tion of post-treatment gametocytaemia among children 
initially harbouring crt T76 parasites. Although this was 
not expected and would reflect an extraordinary rapid
process, both observations may be influenced by the 
small sample size.
Conclusion
The present data provide evidence supporting a hypothe­
sis on a connection between resistance to CQ and SP sug­
gesting that both, CQ and SP resistance favour 
transmission. This needs to be verified by carefully 
designed longitudinal studies in regions of differing levels 
of drug resistance and endemicity. Per se, antimalarial 
treatment must be effective, and more effective than CQ 
and SP, not only to reduce treatment failures but also the 
transmission of potential co-resistance. Eventually, as this 
has been shown to counterbalance enhanced transmis­
sion of resistant parasites [15] the results strongly support 
combinatory treatment including artemisinine-deriva- 
tives.
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